{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:44:34Z","timestamp":1751449474272,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,30]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Psoriasis is an immune-mediated chronic inflammatory skin disease that is rarely complicated by polymyositis in clinical practice. Here, we report a patient with psoriasis, following treatment with Etanercept, who exhibited an increase in creatine kinase (CK) levels and a decline in muscle strength. After combined treatment with methylprednisolone, methotrexate, and Ixekizumab, the psoriasis rash completely subsided and CK levels returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 22-year-old female with systemic erythema and scale itching for 3 months, and her serum CK level was 1711 U\/L without muscle pain and muscle weakness. She was diagnosed with psoriasis and myositis awaiting investigation and was then treated with Etanercept at 50\u2009mg weekly. At the 6-month follow-up with ongoing Etanercept treatment, her serum CK level was elevated to 3465 U\/L. Electromyography and thigh magnetic resonance imaging revealed myositis. After methylprednisolone and methotrexate tablet treatment for polymyositis, she developed pulmonary pneumonia, and methotrexate and methylprednisolone tablets were withdrawn. Although the pneumonia was controlled, the facial erythema, plaques, scales, and rash gradually increased and spread all over the body. Moreover, gastrocnemius pain and fatigue persisted. The patient was treated with subcutaneous injection of 160\u2009mg of Ixekizumab combined with methylprednisolone tablet (8\u2009mg\/d), after 2 weeks, the dosage was reduced to 80\u2009mg once every 2 weeks, and the patient\u2019s psoriastic rash had completely disappeared after 4 weeks. The patient continued to receive subcutaneous injections of Ixekizumab 80\u2009mg once a month and methylprednisolone tablet 6\u2009mg every day. Six months later, no rash recurrence was noted and her CK level was within the normal range.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with psoriasis with polymyositis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After combined treatment with methylprednisolone, methotrexate, and Ixekizumab, the psoriasis rash completely subsided and CK levels returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Our case shows that Ixekizumab is an effective treatment for psoriasis complicated with polymyositis, which is worth clinical application.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Although Etanercept can be used to treat psoriasis and dermatomyositis, it can also aggravate the myositis. Ixekizumab is an effective treatment for psoriasis complicated by polymyositis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042550","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:01:21Z","timestamp":1749758481000},"page":"e42550","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Psoriasis complicated with polymyositis successfully treated with Ixekizumab: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6829-5923","authenticated-orcid":false,"given":"Shengli","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-2440","authenticated-orcid":false,"given":"Jifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","article-title":"Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.","volume":"18","author":"Toussirot","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-016-0246-9","article-title":"Efficacy and safety of switching to Ixekizumab in etanercept non-responders: a subanalysis from Two Phase III Randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and-3).","volume":"18","author":"Blauvelt","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.alit.2017.09.001","article-title":"A case of clinically amyopathic dermatomyositis that developed during anti-TNF-\u03b1 therapy for rheumatoid arthritis.","volume":"67","author":"Takata","year":"2018","journal-title":"Allergol Int"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","article-title":"Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.","volume":"149","author":"Liu","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R6-20250612","first-page":"656","article-title":"Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis.","volume":"37","author":"Silva","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.12788\/j.sder.0070","article-title":"Tumor necrosis factor inhibitors in psoriasis: an update.","volume":"33","author":"Kerdel","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature.","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:01:23Z","timestamp":1749758483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":8,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042550","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}